+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sustained Release Injectables Market - Global Forecast 2026-2032- Product Image
Sustained Release Injectables Market - Global Forecast 2026-2032- Product Image
Sale

Sustained Release Injectables Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533434
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sustained Release Injectables Market is projected to reach USD 2.60 Billion in 2026. It is expected to continue growing at a CAGR of 7.24%, reaching USD 4.01 Billion by 2032.

Sustained release injectables are reshaping drug delivery by extending therapeutic exposure from days to months, reducing dosing burden, and supporting adherence in chronic diseases, behavioral health, oncology, endocrine disorders, infectious disease prevention, and contraception. The category includes long-acting injectables, depot formulations, polymeric microspheres, in situ forming depots, lipid-based systems, implants, and nanoparticle-enabled platforms.

Demand is supported by verified public-health fundamentals: the World Health Organization reports that noncommunicable diseases account for most global deaths, while regulators, including the FDA and EMA, continue to evaluate long-acting products that can improve persistence and simplify care delivery. For pharmaceutical manufacturers, sustained release injectables combine high clinical value with demanding formulation science, aseptic manufacturing, sterility assurance, controlled-release analytics, and lifecycle management requirements.

Transformative Shifts in the Sustained Release Injectable Landscape

The sustained release injectable landscape is moving from convenience-driven reformulation toward evidence-led therapeutic redesign. Approved long-acting therapies in antipsychotics, HIV treatment and prevention, hormone modulation, substance-use disorder, contraception, and metabolic disease have demonstrated that extended dosing intervals can change patient engagement, clinical workflows, and payer value discussions.

At the same time, the sector is becoming more technically specialized. Developers must align release kinetics, particle-size distribution, polymer degradation, syringeability, extractables and leachables, cold-chain needs, sterilization strategy, and bioequivalence approaches. The most competitive development models integrate formulation, device, analytics, manufacturing, regulatory, and patient-support capabilities earlier in development rather than treating sustained release as a late-stage product extension.

Cumulative Impact of Artificial Intelligence on Product Development

Artificial intelligence is increasingly influencing sustained release injectable development across molecule selection, excipient screening, release-profile prediction, stability assessment, scale-up risk evaluation, and manufacturing deviation analysis. Machine learning models can help prioritize formulation variables and reduce experimental cycles when trained on high-quality physicochemical, stability, dissolution, in vitro release, and pharmacokinetic datasets.

The cumulative impact is strongest when AI is embedded within validated quality systems. In silico modeling, digital twins, process analytical technology, and automated visual inspection can improve consistency, but regulated implementation still requires data integrity, model explainability, human oversight, cybersecurity controls, and compliance with FDA, EMA, ICH, and GxP expectations. AI is therefore an accelerator for better decisions, not a substitute for robust CMC evidence.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming a critical growth engine for sustained release injectables as China, India, Japan, South Korea, and Australia combine large patient populations, expanding specialty-care access, and strong manufacturing capabilities. China and India provide scale in active pharmaceutical ingredients, generics, formulation development, and contract manufacturing, while Japan, South Korea, and Australia contribute advanced clinical, regulatory, biologics, and quality-system infrastructure. Regional demand is supported by the high burden of chronic disease, rising use of specialty medicines, and public-sector efforts to strengthen domestic pharmaceutical supply.

North America remains a leading innovation and commercialization hub, supported by established FDA regulatory pathways, specialty pharmacy channels, clinical-trial infrastructure, and documented adoption of long-acting therapies in mental health, HIV, contraception, and chronic disease management. Europe benefits from EMA scientific procedures, country-level health technology assessment systems, pharmacovigilance rigor, and strong sterile injectable manufacturing clusters. Latin America, led by Brazil and Mexico, shows demand linked to public-health programs, urban specialty care, and growing experience with complex injectables, while the Middle East is prioritizing healthcare investment, centralized procurement, local fill-finish capacity, and reliable cold-chain systems. Across Africa, access strategies are shaped by essential medicines programs, infectious disease prevention needs, donor-supported procurement mechanisms, and the practical value of long-acting products that reduce visit frequency and strengthen continuity of care.

Key Group Insights Shaping Demand and Supply

ASEAN markets are gaining relevance as regulatory convergence initiatives, hospital modernization, and domestic pharmaceutical investment improve the feasibility of launching complex injectables across Southeast Asia. Demand patterns differ by country, but rising noncommunicable disease prevalence, expanding universal health coverage efforts, and growing tertiary-care capacity support interest in long-acting injectable therapies. The GCC is characterized by centralized procurement, high healthcare spending in several member states, national industrialization plans, and growing interest in local fill-finish, biologics, and sterile injectable capacity.

The European Union provides a harmonized regulatory base through EMA procedures while still requiring country-level pricing, reimbursement, and health technology assessment execution. BRICS countries combine large disease burdens with manufacturing scale, policy interest in domestic production, and expanding clinical research capabilities, making localization and affordability important strategic themes. G7 markets remain central for premium innovation, clinical adoption, intellectual-property monetization, and evidence-based reimbursement, while NATO-aligned supply-chain strategies increasingly emphasize resilience for sterile injectables, critical medicines, and medical countermeasures amid documented concerns over medicine shortages and geopolitical supply disruption.

Key Country Insights for Sustained Release Injectable Strategy

The United States leads in commercialization depth, clinical-trial density, specialty injectable adoption, and regulatory experience with long-acting formulations, while Canada emphasizes evidence-based reimbursement, health technology assessment, and access management. Mexico and Brazil are important Latin American platforms for branded and generic injectables, with Mexico benefiting from proximity to North American supply chains and Brazil offering scale through public procurement, national immunization and public-health infrastructure, and domestic production incentives.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical practice with strong payer scrutiny, making pharmacoeconomic evidence, real-world outcomes, and comparative effectiveness important for sustained release injectable strategy. Russia remains a sizeable market with local-production priorities and demand for essential sterile medicines. China and India are central to patient volume, manufacturing capability, clinical expansion, and policy support for domestic pharmaceutical capacity; Japan rewards quality, safety, and differentiated outcomes; Australia offers a transparent reimbursement environment and strong clinical standards; and South Korea contributes advanced biopharma manufacturing, biosimilar expertise, digital health infrastructure, and high-quality clinical research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications where extended dosing directly improves adherence, persistence, relapse prevention, public-health coverage, or health-system efficiency. Early target-product-profile work should integrate patient preference, injection-site tolerability, dose volume, needle gauge, healthcare professional administration time, storage conditions, disposal requirements, and real-world evidence expectations.

Companies should invest in in vitro release testing, validated analytical methods, scalable aseptic processes, supplier qualification, device compatibility, and sterility assurance before pivotal development. Strategic partnerships with CDMOs, polymer and excipient specialists, device developers, digital adherence platforms, and regional distributors can reduce launch risk. Commercial teams should prepare payer dossiers that link sustained exposure to fewer missed doses, lower care fragmentation, reduced administration burden, and measurable outcomes rather than relying on dosing convenience alone.

Research Methodology

The research methodology is built on a structured secondary research and validation framework using publicly available regulatory, scientific, and healthcare sources. Core references include FDA databases and guidance documents, EMA European public assessment reports, WHO health statistics, OECD and World Bank indicators, national reimbursement publications, pharmacopoeial references, and publicly available regulatory disclosures.

Insights are synthesized through triangulation across therapeutic adoption, regulatory pathways, manufacturing feasibility, clinical evidence, formulation complexity, quality requirements, and regional access conditions. Market statements avoid unsupported revenue projections and focus on verified drivers such as disease burden, approved product precedents, sterile manufacturing constraints, medicine-shortage documentation, public procurement behavior, and policy priorities in medicines access, domestic production, and supply-chain resilience.

Conclusion

Sustained release injectables are becoming a strategic pillar of modern drug delivery because they address a verified healthcare challenge: many chronic and preventive therapies fail when dosing is frequent, complex, or poorly aligned with patient behavior. Long-acting injectable formulations can strengthen adherence, simplify care models, support preventive health programs, and create differentiated product lifecycles when backed by strong clinical and manufacturing evidence.

Future leadership will depend on evidence quality, manufacturability, regulatory execution, regional access planning, and disciplined use of AI-enabled development tools. Organizations that combine formulation science with quality-by-design principles, patient-centered design, robust supply networks, and credible real-world evidence will be best positioned to create value in the sustained release injectable market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Sustained Release Injectables Market, by Product Type
7.1. Introduction
7.2. Cartridges
7.3. Implantable Pumps
7.4. Pre-Filled Syringes
7.5. Unfilled Vials
8. Sustained Release Injectables Market, by Polymer Type
8.1. Introduction
8.2. Biodegradable Polymers
8.2.1. PCL
8.2.2. PLA
8.2.3. PLGA
8.3. Non-Biodegradable Polymers
8.3.1. Polyethylene
8.3.2. Polysiloxanes
9. Sustained Release Injectables Market, by Route Of Administration
9.1. Introduction
9.2. Epidural
9.3. Intramuscular
9.4. Intravitreal
9.5. Subcutaneous
10. Sustained Release Injectables Market, by Application
10.1. Introduction
10.2. Hormonal Therapies
10.3. Oncology
10.3.1. Hematological Malignancies
10.3.2. Solid Tumors
10.3.2.1. Breast Cancer
10.3.2.2. Lung Cancer
10.4. Pain Management
10.5. Vaccines
11. Sustained Release Injectables Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Home Healthcare
11.5. Hospitals
12. Sustained Release Injectables Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Sustained Release Injectables Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Sustained Release Injectables Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Alkermes plc
16.3. Amgen Inc.
16.4. Amneal Pharmaceuticals, Inc.
16.5. AstraZeneca PLC
16.6. Bayer AG
16.7. Boehringer Ingelheim International GmbH
16.8. Bristol-Myers Squibb Company
16.9. Catalent, Inc.
16.10. Cipla Ltd.
16.11. Dr. Reddy’s Laboratories Ltd.
16.12. Eli Lilly and Company
16.13. F. Hoffmann-La Roche Ltd
16.14. Gilead Sciences, Inc.
16.15. GlaxoSmithKline plc
16.16. Hikma Pharmaceuticals PLC
16.17. Indivior PLC
16.18. Ipsen S.A.
16.19. Janssen Pharmaceuticals, Inc.
16.20. Johnson & Johnson Services, Inc.
16.21. Lupin Limited
16.22. Merck & Co., Inc.
16.23. Novartis AG
16.24. Novo Nordisk A/S
16.25. Otsuka Pharmaceutical Co., Ltd.
16.26. Pfizer Inc.
16.27. Recipharm AB
16.28. Sanofi S.A.
16.29. Sun Pharmaceutical Industries Ltd.
16.30. Takeda Pharmaceutical Company Limited
16.31. Teva Pharmaceutical Industries Ltd.
16.32. Tolmar, Inc.
16.33. UCB S.A.
16.34. Viatris Inc.
16.35. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL UNFILLED VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL UNFILLED VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL UNFILLED VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PCL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PCL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PCL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PLA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PLA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PLA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PLGA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PLGA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PLGA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL POLYETHYLENE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL POLYETHYLENE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL POLYETHYLENE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL POLYSILOXANES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL POLYSILOXANES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL POLYSILOXANES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL EPIDURAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL EPIDURAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL EPIDURAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVITREAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVITREAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVITREAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 120. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 124. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 125. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 128. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 129. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 144. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 145. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 148. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 149. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 153. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 154. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 155. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 156. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 158. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 159. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 160. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 163. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 164. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 165. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 166. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 169. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 170. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 183. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 184. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 185. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 186. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 189. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 190. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 193. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 194. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 195. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 196. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 199. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 200. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 203. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 204. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 205. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 206. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 209. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 210. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 224. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 225. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 226. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 227. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 229. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 230. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 231. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 234. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 235. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 236. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 237. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 239. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 240. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 241. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 250. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 265. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 266. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 267. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 268. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 270. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 271. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 274. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 275. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 276. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 277. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 279. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 280. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 281. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 294. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 295. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 296. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 297. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 300. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 301. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 304. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 305. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 306. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 307. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 309. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 310. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 311. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 314. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 315. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 316. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 317. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 319. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 320. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 321. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 324. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2017-2032 (USD MILLION)
TABLE 325. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 326. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2017-2032 (USD MILLION)
TABLE 327. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 328. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 329. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 330. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 331. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 334. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE,

Companies Mentioned

  • AbbVie Inc.
  • Alkermes plc
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Catalent, Inc.
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Ipsen S.A.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Recipharm AB
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar, Inc.
  • UCB S.A.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.6 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.01 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

Injectable Drugs Market - Global Forecast 2026-2032 - Product Image

Injectable Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Generic Injectables Market - Global Forecast 2026-2032 - Product Image

Generic Injectables Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Injectable Cytotoxic Drugs - Global Strategic Business Report - Product Image

Injectable Cytotoxic Drugs - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Injectable Drugs Delivery - Global Strategic Business Report - Product Image

Injectable Drugs Delivery - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From

About the Market

The Sustained Release Injectable market is a subset of the Infusions and Injectables market. It is composed of drugs that are administered via injection and are designed to provide a slow and steady release of the active ingredient over a period of time. This type of drug delivery system is beneficial for patients who require a consistent level of medication over a long period of time. It also reduces the number of injections needed, which can be beneficial for patients who have difficulty with frequent injections. The Sustained Release Injectable market is composed of a variety of drugs, including hormones, antibiotics, and analgesics. These drugs are typically administered via intramuscular or subcutaneous injection, and the active ingredient is slowly released over a period of time. Some companies in the Sustained Release Injectable market include Pfizer, Merck, Novartis, and Sanofi. These companies produce a variety of drugs that are designed to provide a slow and steady release of the active ingredient over a period of time. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.